A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

The following is a summary of “Recent advances and applications of optical coherence tomography angiography in diabetic ...

Regeneron Pharmaceuticals (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing the supplemental biologics ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

The open-label, dose-escalation trial will explore ... which are key factors in the pathophysiology of DMO, diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).

Diabetic retinopathy involves the changes for the blood vessels in your eye due to the high sugars that are in your body from diabetes, if you're a diabetic and you notice changes to your vision ...

Background: This study was performed to assess the prevalence of dry eye syndrome and diabetic retinopathy (DR) in type 2 diabetic patients and their contributing factors. Methods: 199 type 2 ...

and diabetic macular edema (DME), and every 8 to 12 weeks for patients with diabetic retinopathy (DR), following 3 initial monthly doses. About EYLEA HD Over a decade ago, Regeneron introduced ...